Advertisement
Canada markets closed

  • S&P/TSX

    22,011.72
    +139.76 (+0.64%)
     

  • S&P 500

    5,070.55
    +59.95 (+1.20%)
     

  • DOW

    38,503.69
    +263.71 (+0.69%)
     

  • CAD/USD

    0.7321
    +0.0001 (+0.01%)
     

  • CRUDE OIL

    83.34
    -0.02 (-0.02%)
     

  • Bitcoin CAD

    90,923.66
    -391.27 (-0.43%)
     

  • CMC Crypto 200

    1,434.93
    +20.17 (+1.43%)
     

  • GOLD FUTURES

    2,332.60
    -9.50 (-0.41%)
     

  • RUSSELL 2000

    2,002.64
    +35.17 (+1.79%)
     

  • 10-Yr Bond

    4.5980
    -0.0250 (-0.54%)
     

  • NASDAQ futures

    17,733.25
    +126.50 (+0.72%)
     

  • VOLATILITY

    15.69
    -1.25 (-7.38%)
     

  • FTSE

    8,044.81
    +20.94 (+0.26%)
     

  • NIKKEI 225

    38,343.51
    +791.35 (+2.11%)
     

  • CAD/EUR

    0.6833
    -0.0003 (-0.04%)
     

Phoenix BioTech, BioNovelus, To Tour Central America and Mexico This Summer

ACCESSWIRE

PHOENIX, AZ / ACCESSWIRE / June 9, 2016 / BioNovelus, Inc. (PINKSHEETS:ONOV - News) is pleased to announce the creation of BioNovelus-CostaRica, a legal entity that will register BioNovelus products for each country in Central America. The registration for Costa Rica should be achieved by the end of the third quarter of 2016.

BioNovelus President/CEO Jean Ekobo has presented biodegradable fungicide CR-10 to the Costa Rican Coffee Trade Association (ICafé). ICafé was chosen to continue testing on three major problems affecting the coffee industry: two fungi, coffee rust ("roya") and "ojo de gallo," and a pest, broca. No other product in the industry has been able to be effective against all three.

BioNovelus CFO, Mark Johnson, and Jean Ekobo met with a prominent distributor of agrochemicals, fertilizers, fungicides, seeds and spraying equipment that reaffirmed their commitment to becoming a distributor of CR-10 in Costa Rica, once the product is registered.

In addition to meeting with CoopeAgri, a cooperative of 14,000 coffee farmers, Jean Ekobo and Enrique Calderon, the local representative of BioNovelus, have met with several potential customers that serve Nestle (Nespresso) and Starbucks.

ADVERTISEMENT

The success of the Costa Rica trip has prompted BioNovelus to schedule visits to Colombia, Mexico, Guatemala, and Honduras this summer. Colombia has 980,000 hectares of coffee plantations, (ten times more than Costa Rica), Mexico has 680,000 hectares, Honduras 282,000 ha, and Guatemala 276,500 ha. All these countries are affected by these coffee fungi and pests.

Corporate Update

BioNovelus is among the four new startups in Arizona to have been selected for its potential growth, job creation, and business model, by the Center for Entrepreneurial Innovation (CEI), a Phoenix-based business incubator, to enter its program.

BioNovelus will receive in-house business development assistance from counselors, mentors and an entrepreneur-in-residence, as well as access to dedicated wet lab and office space, a robust network of investment and entrepreneurial partners, and onsite 3D printing and engineering services. Through August 2015, CEI member companies have created an estimated 145 jobs and earned over $29 million in revenues as well as $11 million in capital investment.

BioNovelus' new address is:

275 North Gateway Drive
Suite 130
Phoenix, AZ 85034

About BioNovelus Inc.

BioNovelus, Inc. (PINKSHEETS:ONOV - News) is a biotech company that honors the environment with an innovative, cost effective, and disruptive technology-based solution to the problems of safety and cleanliness regarding food production and water supply.

Additional Information

For additional information: http://bionovelus.com

Please contact: Nathalie Ekobo,
Marketing & Communications Director

BioNovelus, Inc.:
Skype: bionovelus.inc
+1 602-888-3424
NEkobo@BioNovelus.com

Forward-Looking Statements

This news release includes forward-looking statements covered by the Private Securities Litigation Reform Act of 1995. Because such statements deal with future events, they are subject to various risks and uncertainties and actual results for fiscal year 2015 and beyond could differ materially from the Company's current expectations. Forward-looking statements are identified by words such as "anticipates," "projects," "expects," "plans," "intends," "believes," "estimates," "targets," and other similar expressions that indicate trends and future events.

Factors that could cause the Company's results to differ materially from those expressed in forward-looking statements include, without limitation, variation in demand and acceptance of the Company's products and services, the frequency, magnitude and timing of paper and other raw-material-price changes, general business and economic conditions beyond the Company's control, timing of the completion and integration of acquisitions, the consequences of competitive factors in the marketplace including the ability to attract and retain customers, results of continuous improvement and other cost-containment strategies, and the Company's success in attracting and retaining key personnel. The Company undertakes no obligation to revise or update forward-looking statements as a result of new information, since these statements may no longer be accurate or timely.

Certain statements in this news release may contain forward-looking information within the meaning of Rule 175 under the Securities Act of 1933, and are subject to Rule 3B-6 under the Securities Exchange Act of 1934, and are subject to the safe harbor created by those rules. All statements, other than statements of fact, included in this press release, including, without limitation, statements regarding potential future plans and objectives of the company, are forward-looking statements that involve risks and uncertainties. There can be no assurance that such statements will prove to be accurate and other results and further events could differ materially from those anticipated in such statements. Future events and actual results could differ materially from those set forth in, contemplated by, or underlying the forward-looking statements.

SOURCE: BioNovelus Inc.